Eris Lifesciences Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eris Lifesciences Limited generated cash of $4,860,050,000, which is more than the previous year. Cash used in financing activities reached the amount of $13,797,790,000 last year. Net change in cash is therefore $382,230,000.
Cash Flow
| 2016 | 1.31B | -439.13M | -836.98M |
|---|---|---|---|
| 2018 | 2.34B | -5.90B | 3.63B |
| 2020 | 2.71B | 1.23B | -3.34B |
| 2021 | 3.75B | -3.23B | -823.95M |
| 2023 | 2.91B | -9.82B | 6.88B |
| 2024 | 4.86B | -18.54B | 13.79B |
ERIS.NS Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 560.22M | 508.7M | 673.07M | 75M | 23.43M | 49.99M |
Operating activities | ||||||
Net income | 3.91B | 4.04B | 3.94B | 3.31B | 3.12B | 1.54B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.82B | 1.17B | 429.85M | 502.58M | 256.42M | 203.56M |
Stock-based compensation expense | 7.5M | 31.21M | 11.2M | 16.61M | 0 | 0 |
| Deferred income tax benefit | 7.5M | 31.21M | 11.2M | 16.61M | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -570.93M | -1.17B | 158.96M | -747.86M | -91.59M | -17.03M |
Inventories | -169.4M | 47.44M | -249.91M | 131.78M | 4.16M | 99.83M |
Accounts payable | 909.78M | -104.97M | 25.66M | 159.34M | 270.08M | 0 |
Cash generated by operating activities | 4.86B | 2.91B | 3.75B | 2.71B | 2.34B | 1.31B |
Investing activities | ||||||
Purchases Of Investments | 0 | -300M | -3.73B | -381M | -1.07B | -207.23M |
Investments In Property Plant And Equipment | -1.29B | -8.41B | -257.63M | -1.51B | -250.96M | -236.41M |
Acquisitions Net | -5.66B | -6.55B | -2.81M | -213.73M | -5.27B | 300K |
Cash generated by investing activities | -18.54B | -9.82B | -3.23B | 1.23B | -5.90B | -439.13M |
Financing activities | ||||||
Common Stock Issued | 45.43M | 22.78M | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | -999.11M | -746.79M | -469.79M | 0 | -830.78M |
Repurchases of common stock | 0 | 0 | 0 | -1.01B | 0 | 0 |
Repayments of term debt | 14.63B | 8.17B | -100K | -86.02M | 3.73B | -5M |
Cash used in financing activities | 13.79B | 6.88B | -823.95M | -3.34B | 3.63B | -836.98M |
Net Change In Cash | 382.23M | 51.52M | -303.92M | 598.07M | 82.65M | 38.68M |
Cash at end of period | 942.45M | 560.22M | 369.15M | 673.07M | 106.08M | 88.67M |
| Data source | Data source | Data source | Data source | Data source | Data source |